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Abstract
Biomedical researchers often assume that sponsors, subjects, families, and disease-associated advocacy
groups contribute to research solely because of altruism. This view fails to capture the diverse interests
of many participants in the emerging research enterprise. In the past two decades, patient groups have
become increasingly active in the promotion and facilitation of genetics research. Simultaneously, a
significant shift of academic biomedical science toward commercialization has occurred, spurred by U.S.
federal policy changes.
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Protecting Subjects’ Interests in Genetics Research
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Biomedical researchers often assume that sponsors, subjects, families, and disease-associated advocacy groups
contribute to research solely because of altruism. This view fails to capture the diverse interests of many participants
in the emerging research enterprise. In the past two decades, patient groups have become increasingly active in the
promotion and facilitation of genetics research. Simultaneously, a significant shift of academic biomedical science
toward commercialization has occurred, spurred by U.S. federal policy changes. The concurrent rise in both the
roles that subjects play and the commercial interests they have presents numerous ethical challenges. We examine
the interests of different research participants, finding that these interests are not addressed by current policies and
practices. We conclude that all participants should be given a voice in decisions affecting ownership, access to, and
use of commercialized products and services, and that researchers and institutions should negotiate issues relating
to control of research results and the sharing of benefits before the research is performed.

Discoveries made with your DNA samples may be patented by us and
the University. These patents may be sold or licensed, which could give a
company the sole right to make and sell products or offer testing based on
the discovery. Royalties may be paid to us, the University, and the Sponsor.
It is not our intent to share any of these possible royalties with you.

The paragraph above is from a prototypical consent form
for DNA banking in genetics research. The statement reflects the prevalent view among researchers, institutions,
and sponsors in regard to the allocation of intellectual
property rights and associated monies that result from
such research (Beskow et al. 2001). As reflected in standardized consent forms, current institutional policies and
practices that govern biomedical research assume that
subjects act solely because of altruism and that the sole
duty of researchers is to disclose their intentions, rather
than to recognize any interest of subjects in commercial
products that may result from the research. This view was
fostered by the California Supreme Court, when, more
than a decade ago, it held that John Moore did not have
a property interest in his tissues, but only had a right to
be informed about both the intent to develop a cell line
and the potential commercial interests of the clinician researchers with whom he interacted (Moore v. Regents of
the University of California 1990).
This view fails to capture the myriad interests and
motives of the different actors involved in the research
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enterprise, including academic scientists, public and private sponsors, commercial institutions, patient groups,
and research subjects themselves. A consideration of
these interests reveals many areas of potential conflict.
The resolution of these issues early in the research process may facilitate research and better protect the rights
and interests of patients and research subjects.
The Emerging Collaborative-Research Enterprise
Patient groups are becoming more active in the promotion and facilitation of preclinical and clinical research. Although patient groups have long played a key
role through participation in research (e.g., by helping
coordinate subject identification and recruitment and
fund-raising to support research), a new type of relationship is emerging as groups become key players in
the promotion of studies of the causal role of genetics
in diseases (Lindee 2000). This developing role has occurred concurrently with two other significant changes
in biomedical research: the creation and rapid evolution
of technology transfer and the explosion in biotechnology science and investment. The concurrent rise in research subjects’ roles and commercial interests raises
new ethical and policy challenges.
Various groups have started or are starting foundations for the funding of research, compiling diseasespecific registries of patients and genealogical and med965
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ical databases, establishing tissue and DNA banks to
provide resources crucial for genetics research, and developing scientific expertise that can make substantive
contributions to the direction and performance of research. Demonstrating the number and breadth of interest groups, the Genetic Alliance lists more than 500
members from family and patient support groups, advocacy groups, health professionals, universities, companies, and the government. Individuals involved in
these initiatives and their families often participate directly in research. The resultant close collaborative relationships with scientists greatly facilitate targeted research by providing access to affected communities,
giving highly motivated assistance in identifying and
soliciting potential participants from these communities, giving credibility to the researchers that can increase trust and participation, and sharing the costs of
recruitment.
Several recent examples illustrate the range of subject
and group involvement. These examples suggest that
the nature of the relationships that exist between patients, their families and the larger community of families at risk, and the genetics research community is
changing. These cases reveal that the participants can
have different interests in the outcomes of research and
that these interests may conflict with those of other actors. By identifying the interests in the products and
benefits of research that are at stake, we hope to begin
a conversation and negotiation among those involved
to develop policies for protecting the interests of subjects
that will allocate the costs, burdens, and benefits in an
equitable manner.

ent 5,679,635, which covered all diagnostic and therapeutic uses of the gene in October 1997. MCH embarked on what the families believed to be a restrictive
and unduly expensive licensing program. On October
30, 2000, three involved families, the National Tay
Sachs and Allied Diseases Association, and Dor Yeshorim filed suit against MCH, in an attempt to prevent
continued use of the patent in a manner that the plaintiffs believe is immoral, unfair to those who made the
research possible, and likely to restrict access to the
test (Greenberg v. Miami Children’s Hospital 2000;
Marshall 2000).

Canavan Disease

a-1-Antitrypsin Deficiency

Dan and Debbie Greenberg and their children and
more than 150 other families from around the world
participated in an extensive collaborative relationship
with Dr. Reuben Matalon that led fruitfully to the discovery of the aspartoacylase gene in 1993 (Kaul et al.
1993). These families participated in the studies; helped
identify, solicit, and collect blood samples from other
afflicted families; and secured research support from the
Canavan Foundation, the National Tay Sachs and Allied
Diseases Association, the United Leukodystrophy Foundation, and various local groups. Rabbi Josef Ekstein,
Executive Director of Dor Yeshorim–Committee for
Prevention of Jewish Genetic Diseases, in Brooklyn,
provided access to approximately six thousand stored
blood samples. These were used by the researchers to
rapidly identify several mutations in Ashkenazi Jewish
families and to estimate population frequencies (Kaul
et al. 1994).
Unbeknownst to the families, the researchers and
Miami Children’s Hospital (MCH) secured U.S. pat-

The Alpha-1 Foundation was created to expedite research into therapies and a cure for a-1-antitrypsin deficiency. The Foundation has provided monetary research support, it has created a confidential research
registry as well as a DNA bank, it sponsors annual research symposia, and it helped secure funding for a program and faculty chair at the University of Florida. The
Foundation is developing proactive policies that will best
protect the interests of the a-1-antitrypsin deficiency
community in new discoveries resulting from collaborative and sponsored research, while directly promoting
research for treatments and a cure.

Pseudoxanthoma Elasticum (PXE)
In the mid-1990s, Sharon Terry created PXE International (Kolata 2000b). The foundation helped identify
and solicit participation from affected families, established a registry and a repository, and raised money to
support studies through use of these resources. PXE International negotiated with researchers to whom they
provided support and access to biomaterials for research, and through use of Material Transfer Agreements, retained authorship in any papers and ownership
rights in any patents, to ensure broad and affordable
availability of the test and to retain influence over downstream development (Pennisi 2000; Smaglik 2000). The
gene implicated in the disorder was identified in early
2000 (Bergen et al. 2000; Le Saux et al. 2000), and the
foundation’s ownership increases the likelihood that the
interests of those most affected by PXE will be represented in decisions about licensing and treatment research and development.

Recognizing Interests in Genetics Research
The current “market” in genetics research includes patients and families, disease-associated advocacy groups,
foundations, governmental agencies such as the National
Institutes of Health (NIH), researchers, universities, biotechnology firms, and pharmaceutical companies. All
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have common goals: the discovery of the genetic causes
of disease, the broad availability of testing to patients,
and, ultimately, the development of treatments or cures.
However, individuals and groups have more diverse interests, motivations, and incentives for performing,
funding, participating in, and promoting research. It is
important to understand those interests to develop strategies that best satisfy all of the parties. Of course, not
all interests and motives can be captured in an analysis
such as this, but our generalizations may help the understanding of what the limits of our knowledge are in
this area, by spurring conversation among interested
parties, and may provide a foundation for basic policies
that can be adapted to different needs and situations.
The key interests that typify the contributions of
firms, foundations, government, researchers, advocacy
groups, and patient participants are presented in figure
1 and include the following:
1. Financial return. Contributions to research are
treated as investments on which a monetary reward and
reasonable rate of return is expected and, to the extent
feasible, negotiated. The type of investments may be financial or otherwise, but here the payoffs are expected
to be monetary.
2. Therapy. Various actors invest money, time, expertise, and other resources for fundamental knowledge
about the disease, development and provision of carrier,
prenatal, and population-screening tests, and ultimately
development of preventative measures, treatments, and
cures. The motive here is self-interest in treatment or
cure for a disease.
3. Ego (self-esteem). Motivation comes from the intangible rewards of reputation, notoriety, prizes, and
awards.
4. Intellectual curiosity. Reflecting the very basic scientific motives of seeking knowledge, making discoveries, and understanding the world around us, intellectual curiosity is distinguished from therapy, in that
knowledge is valued in itself, independently of its instrumental value as a relief from disease.
5. Altruism. Contributions of money, time, and active research promotion and participation are treated as
an unalloyed gift to help those who will most benefit in
the future from the potential fruits of the research. Under
a pure altruism model, there is no expectation of return
or personal benefit.
6. Duty. Individuals, professionals, and organizations are obliged to act for the good of others. Patients
and those who act as their advocates may feel obligated
to promote and participate in research for themselves,
for their families, and for those in the affected or at-risk
disease community; government may be compelled to
support research on behalf of citizens who are or may

Figure 1

A heuristic method for consideration of interests of
various actors involved in genetics research. All actors may be influenced in part by any of these factors, but we posit that some interests
will dominate, as suggested by deeper shading of the intersecting boxes.

be afflicted, to promote the public health, or even for
reasons of foreign policy or national security.
Figure 1 graphically depicts the contrasting interests of
different research participants, providing a heuristic
method that permits the express consideration of interests. From our consideration of these interests, we have
drawn various inferences.
Biotechnology and pharmaceutical firms will invest
risk capital in downstream research and development,
such as taking a promising drug through animal and
human testing, only if they are assured of some measure
of market exclusivity. Any retained interests of research
collaborators or of those who made upstream discoveries increases the risk and depresses the motivation for
the firm to undertake a development effort (Heller and
Eisenberg 1998). The firm rightfully operates for the
purpose of earning a return on its investment, and the
motivations for performing research are largely—if not
entirely—financial. We believe, however, that the firm
should be willing to compensate those who contribute
to its research and development efforts, but demands
must be reasonable in relation to the contributions, the
likely payoffs, and the risks of the research. Simply, any
economic actor who draws on and profits from resources such as public funds or participation by collaborating disease-associated advocacy groups should not
be freely permitted to use and profit from those public
and private resources without paying for them.
Understanding the motives and interests of universities is more problematic. Arguably, the primary purpose of a research university is to contribute to learning
and development of new knowledge. These institutions
are typically nonprofit, reflecting that they have duties
to society to contribute to the public welfare. But the
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institutions have also become increasingly capitalist
ventures, centered around technology transfer. Technology-transfer departments are permitted by federal
law to cover patenting and licensing expenses with royalty income and typically will return portions of excess
revenue to faculty and their departments, as well as to
the university itself for educational and research purposes (U.S. Code 2001). Universities, then, may be
viewed as schizophrenic, defending the open and free
sharing of ideas traditionally valued in the academy
while simultaneously pursuing the protection of intellectual property and profits.
Technology-transfer programs have, in turn, created
a monetary incentive for researchers themselves, who
can earn quite substantial sums from inventions licensed
to industry as well as from more-direct commercial ties,
such as equity ownership in commercial ventures. Despite growing concerns about financial conflicts of interest (Cho et al. 2000; DeAngelis 2000), the incidence
of financial incentives and relationships has become
more prevalent within the biomedical research community (Krimsky et al. 1996; Angell 2000). We posit
that government and university researchers remain primarily motivated by intellectual curiosity and academic
freedom, for they likely could earn higher salaries in
industry (Kreeger 2001).
One of the most difficult issues that NIH, other federal
and state funding agencies, and nonprofit foundations
face is the assurance that their financial sponsorship of
research promotes the greatest public good. On the one
hand, patenting and technology transfer are viewed as
effective tools for promoting disclosure of inventions,
spurring investment, rewarding success, and moving basic research off the bench and into the marketplace. Intellectual property rights can ensure firms the exclusivity
they need to justify expenditures of risk capital for development of marketable products and services. On the
other hand, these public institutions—along with patients
and advocacy organizations—should be wary of having
their expenditures totally appropriated by private firms
or universities. Although citizens, patients, and patients’
advocates want treatments and cures, they also want
these to be available at reasonable prices so that they will
be broadly accessible by the community. They also do
not want to be made to pay twice for an invention resulting from research to which they materially contributed, with financial, scientific, participatory, or other
kinds of assistance—once through their direct support
and “again through higher monopoly prices and restricted supply” (Eisenberg 1996). Justice concerns arise
if the costs of products are set too high and result in
material inequities in access by participants.
Of course, it is problematic to assume that government, private foundations, or patient advocacy groups
established by affected families will necessarily reflect
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the interests and values of those afflicted with a particular disease. These groups often reflect the interests and
perspectives of a relatively small number in the community who happen to be particularly active. Sometimes, competing goals and priorities emerge that lead
to the creation of separate institutions. In several cases,
separate foundations have evolved, with one focusing
on issues such as political advocacy, prevention, and
education while another seeks the development of therapies and a cure.
Although we cannot say that the interests of patients
and advocacy groups are identical, we believe that these
organizations are the best situated to represent, protect,
and serve the interests of those most affected. First, for
genetic diseases, there is a sense in which the affected
families have “voted.” As in the case of PXE, families
have joined the group, put their names in a registry, and
perhaps even deposited their genetic material for research, clearly indicating support for the institution and
its representation of their interests. Second, other institutions and individuals (e.g., companies, researchers,
and universities) do not have the interests of the affected
families as their primary interests. As we noted above,
companies have financial obligations to their stockholders and to the bottom line. Researchers have obligations to develop knowledge and to meet the needs
of their universities. Only the patient advocacy and support groups have the interests of the affected families
as their primary interests, even if they have other interests as well.
The difficult balancing suggested above has led to
policies—particularly within the federal government—
that favor nonexclusive over exclusive licensing, except
in cases in which substantial investment farther downstream is required to bring an invention to market (Katz
and Merz 2001). In the 1980s, there was also a regulatory attempt to require the “reasonable pricing” of
products developed under Cooperative Research and
Development Agreements between industry and the federal government (Brody 1996). The financial risk posed
by such conditions were viewed as an impediment to
downstream investment, and these requirements were
dropped. Notwithstanding, the federal government does
not give away its inventions; the NIH collected royalties
of more than $50 million in fiscal year 2000, which
funds are used to reward inventors, pay licensing expenses in the Institutes and Centers, and sponsor educational and research activities (Office of Technology
Transfer, PHS/NIH).
To the extent that royalties—including those paid to
the government—raise prices to consumers, there is a
fundamental justice issue in how such royalties are distributed. If the royalties are used to fund downstream
development—say, of therapies, the costs of these efforts
will effectively be internalized to the community most
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likely to benefit from them. This should be acceptable
to the community, as long as the costs do not lead to
material inequities in access. If the money is, instead,
used to reward prior discovery or treated as profit or
other return on the contribution of the community, then
it may be less acceptable. In our view, fairness demands
that profits be distributed among those who contributed
to the research in an equitable manner. The patient community may not want a financial return, instead preferring to have an influence on access, pricing, and the
terms guiding ownership and control of downstream
developments.
Current policies and practices in research largely reflect none of these interests, and the default stipulation
noted in the beginning of this essay that there will be
no sharing of financial returns with subjects fails to
respect the contributions, or protect the interests, of
subjects and the disease communities they seek to help
(Weijer and Emanuel 2000). Strategies and policies that
respect the contributions of the many involved parties
need to be developed. For example, for products resulting from population-based studies, the Human Genome Organisation (HUGO) Ethics Committee recommended that ∼1%–3% of net profits be returned to
the populations, to support humanitarian aid or health
care infrastructure (HUGO Ethics Committee 2000;
Weijer 2000; Berg 2001). This rate was arbitrarily chosen and does not reflect any economic analysis of relative contribution or fairness. Others have recommended that even greater amounts be shared with
subjects (Weir and Horton 1995). As a very-well-publicized example, deCODE Genetics of Iceland executed
an agreement with the Icelandic government in 2000.
This license granted, to deCODE, the exclusive use of
a centrally compiled population health database, which
deCODE will combine with proprietary genealogic and
genetic databases. In return, deCODE will pay all expenses incurred by the government that are related to
deCODE’s effort to build and maintain the central
database—as well as an annual inflation-adjusted payment of 70 million KR (currently slightly less than
$700,000) and 6% of its annual pretax profit, up to an
additional 70 million KR (Icelandic Ministry of Health
and Social Security 2000). To put these figures in context, we compare them to Iceland’s total public expenditure on health, which was slightly more than 40 billion KR in 1998 (National Economics Institute,
Iceland). Similar policies for benefit sharing were under
discussion prior to the collapse, in December 2000, of
the Framingham Genomics initiative (Kolata 2000a;
Rosenberg 2001) and have been used to recognize the
contributions of individuals and agrarian communities
in the developing world for their “traditional knowledge” and technology relating to rare and useful agricultural stock (Gupta 1998).
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We believe it is unacceptable to presume that patients,
subjects, disease-associated advocacy groups, foundations, and government (and, in turn, taxpayers) are all
pure altruists, as policies and practices now do presume,
especially when these stakeholders have contributed in
a meaningful way to the research enterprise. It is unfair
to these groups for their “investments” to be wholly
appropriated by firms or universities with no commitment to return to the community something of value
that they can both access and afford. We believe that
there has been a market failure with respect to the value
added to the research enterprise by patient and subject
groups, and ways should be found to recognize and
reward their contributions. What that return should be
will vary depending upon the relative contributions
made.
Of course, there are economic concerns and practical
problems with the general claim that subjects should
share in the financial rewards of research. Subjects often
stand to benefit indirectly as consumers from any new
knowledge and therapies that result from research in
which they participate. This is a reasonable claim as
long as prices neither extract exorbitant profits from the
subjects nor create unfair limitations on access. In addition, the contribution of individual subjects may be
quite minimal, given that they bear little physical, psychosocial, or financial risk from the research. Subjects
could be compensated by up-front payments for their
time, pain, and effort, and, although this may make
research more expensive because it is not contingent on
the success of the studies, such compensation is a reasonable way to acknowledge individuals’ roles and the
expected value of their contributions. Alternatively, providing individuals with any share of potential profits
(e.g., royalties) may simply be unmanageable, and the
burden of such royalties might provide a disincentive
to downstream investment unless they are reasonable
and manageable. A middle ground would be to distribute, for example, a single share of stock in any biotechnology business venture associated with the research, because it might be worth very little unless the
research is successful. Perhaps a new class of preferred
subject-class stock could be created for this purpose.
Thus, unless there is some group that represents participants, there may be no good way to recognize and
reward individuals’ contributions. Of course, representative organizations are not always present or involved.
Although there are many disease-associated advocacy
groups, there remain many diseases that have either no
collective representation or limited collective representation, and many individuals may not be affiliated with
the groups that do exist. Nonetheless, when an advocacy group is present, it is likely that researchers will
work with the group if they see that the group increases
the ability to perform their research. If the group con-
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tributes too little or demands too much, then researchers
may look for individual participants separate from the
group. Advocacy groups thus serve two functions: adding value by facilitating research and providing a collective voice to individual participants, backed by the
power to negotiate and frame the ways in which research and commercialization take place.
Entities involved in the commercial aspects of research (including companies and universities that develop intellectual property portfolios from which royalty revenues can be earned) should be expected, as a
matter of public policy and research ethics practice, to
openly negotiate with foundations and disease-associated advocacy group and to resolve issues regarding
ownership, control of downstream use, limits on financial profit-taking from inventions, equitable profit sharing, and other acknowledgments of all contributions
before the research is done. When individuals participate, researchers and institutional review boards should
consider the value that their contribution has toward
the performance of the research and should provide just
compensation. The claims made herein about benefits
sharing are based purely in equity and not property or
other rights; to put it simply, we believe it is the right
thing to do. For their part, subjects and disease foundations must also be reasonable about what their contributions are worth. Much more work needs to be done
to evaluate the relative value of contributions, perhaps
with the goal of the development of standards to be
used in these negotiations.
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